

## Title (en)

TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY

## Title (de)

BEHANDLUNG VON PD-L1-NEGATIVEM MELANOM UNTER VERWENDUNG EINES ANTI-PD-1-ANTIKÖRPERS UND EINES ANTI-CTLA-4-ANTIKÖRPERS

## Title (fr)

TRAITEMENT DU MÉLANOME PD-L1 NÉGATIF À L'AIDE D'UN ANTICORPS ANTI-PD-1 ET D'UN ANTICORPS ANTI-CTLA-4

## Publication

**EP 3988571 A1 20220427 (EN)**

## Application

**EP 21198377 A 20160428**

## Priority

- US 201562153973 P 20150428
- EP 16725959 A 20160428
- US 2016029877 W 20160428

## Abstract (en)

The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

## IPC 8 full level

**C07K 16/28** (2006.01); **A61P 35/00** (2006.01)

## CPC (source: EP KR US)

**A61K 39/39558** (2013.01 - KR US); **A61K 45/06** (2013.01 - US); **A61P 17/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07K 16/2818** (2013.01 - EP KR US); **G01N 33/5743** (2013.01 - KR US); **G01N 33/577** (2013.01 - KR US); **A61K 45/06** (2013.01 - KR); **A61K 2039/507** (2013.01 - EP KR US); **A61K 2039/545** (2013.01 - EP KR US); **A61K 2039/55** (2013.01 - EP KR US); **C07K 2317/21** (2013.01 - KR US); **C07K 2317/92** (2013.01 - KR US); **G01N 2333/70503** (2013.01 - KR US)

## Citation (applicant)

- US 8008449 B2 20110830 - KORMAN ALAN J [US], et al
- US 8779105 B2 20140715 - KORMAN ALAN J [US], et al
- US 6808710 B1 20041026 - WOOD CLIVE [US], et al
- US 7488802 B2 20090210 - COLLINS MARY [US], et al
- US 8168757 B2 20120501 - FINNEFROCK ADAM C [US], et al
- US 8354509 B2 20130115 - CARVEN GREGORY JOHN [US], et al
- WO 2012145493 A1 20121026 - AMPLIMMUNE INC [US], et al
- US 8900587 B2 20141202 - CARVEN GREGORY JOHN [US], et al
- US 8609089 B2 20131217 - LANGERMANN SOLOMON [US], et al
- US 2013017199 A1 20130117 - LANGERMANN SOLOMON [US]
- US 8686119 B2 20140401 - ROTEM-YEHUDAR RINAT [IL], et al
- WO 2013014668 A1 20130131 - CURETECH LTD [IL], et al
- WO 2013173223 A1 20131121 - BRISTOL MYERS SQUIBB CO [US]
- US 7943743 B2 20110517 - KORMAN ALAN J [US], et al
- US 8217149 B2 20120710 - IRVING BRYAN [US], et al
- US 6984720 B1 20060110 - KORMAN ALAN J [US], et al
- US 7605238 B2 20091020 - KORMAN ALAN J [US], et al
- US 5977318 A 19991102 - LINSLEY PETER S [US], et al
- US 6051227 A 20000418 - ALLISON JAMES PATRICK [US], et al
- US 6682736 B1 20040127 - HANSON DOUGLAS CHARLES [US], et al
- US 7034121 B2 20060425 - CARRENO BEATRIZ M [US], et al
- WO 2012122444 A1 20120913 - PROVECTUS PHARMACEUTICALS INC [US], et al
- US 2012263677 A1 20121018 - EAGLE CRAIG J [US], et al
- WO 2007113648 A2 20071011 - PFIZER PROD INC [US], et al
- US 201561153973 P
- SJOBLÖM ET AL., SCIENCE, vol. 314, 2006, pages 268 - 74
- DONG ET AL., NATURE MED., vol. 8, no. 8, 2002, pages 793 - 800
- "The Dictionary of Cell and Molecular Biology", 1999, ACADEMIC PRESS
- "Oxford Dictionary Of Biochemistry And Molecular Biology", 2000, OXFORD UNIVERSITY PRESS
- "GenBank", Database accession no. AAB59385
- GARBE ET AL., EUR. J. CANCER., vol. 48, no. 15, 2012, pages 2375 - 90
- SIEGEL ET AL., CA CANCER J. CLIN., vol. 63, no. 1, 2013, pages 11 - 30
- CONDEELISWEISSLEDER, COLD SPRING HARB. PERSPECT. BIOL., vol. 2, no. 12, 2010, pages a003848
- MCCABEWU, CANCER BIOTHER. RADIOPHARM., vol. 25, no. 3, 2010, pages 253 - 61
- OLAFSEN ET AL., PROTEIN ENG. DES. SEL., vol. 23, no. 4, 2010, pages 243 - 9
- TAUBE ET AL., SCI. TRANSL. MED., vol. 4, no. 127, 2012, pages 127 - 37
- WANG ET AL., CANCER IMMUNOL RES., vol. 2, no. 9, 2014, pages 846 - 56
- TOPALIAN ET AL., N ENGL J MED, vol. 366, 2012, pages 2443 - 54
- HERBST ET AL., J CLIN ONCOL, vol. 31, 2013, pages 3000
- KHLEIF, PROCEEDINGS FROM THE EUROPEAN CANCER CONGRESS, 27 September 2013 (2013-09-27)
- HAMANISHI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 104, no. 9, 2007, pages 3360 - 3365
- GADIOT ET AL., CANCER, vol. 117, no. 10, 2011, pages 2192 - 2201

## Citation (search report)

- [I] US 2013309250 A1 20131121 - COGSWELL JOHN [US], et al

- [I] P. A. OTT ET AL: "CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients", CLINICAL CANCER RESEARCH, vol. 19, no. 19, 1 October 2013 (2013-10-01), pages 5300 - 5309, XP055200528, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-0143
- [I] G. K. PHILIPS ET AL: "Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies", INTERNATIONAL IMMUNOLOGY., vol. 27, no. 1, 16 October 2014 (2014-10-16), GB, pages 39 - 46, XP055217958, ISSN: 0953-8178, DOI: 10.1093/intimm/dxu095
- [I] MAHONEY KATHLEEN M ET AL: "The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.", CLINICAL THERAPEUTICS 1 APR 2015, vol. 37, no. 4, 1 April 2015 (2015-04-01), pages 764 - 782, XP055285031, ISSN: 1879-114X
- [I] JEDD D. WOLCHOK ET AL: "Nivolumab plus Ipilimumab in Advanced Melanoma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, no. 2, 11 July 2013 (2013-07-11), pages 122 - 133, XP055182024, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1302369
- [I] MARZUKA ALEXANDER ET AL: "Melanoma Treatments: Advances and Mechanisms.", JOURNAL OF CELLULAR PHYSIOLOGY NOV 2015, vol. 230, no. 11, 22 April 2015 (2015-04-22), pages 2626 - 2633, XP002759396, ISSN: 1097-4652, DOI: 10.1002/jcp.25019
- [I] PAOLO A ASCIERTO ET AL: "The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 3 March 2013 (2013-03-03), pages 54, XP021142097, ISSN: 1479-5876, DOI: 10.1186/1479-5876-11-54
- [A] P. A. ASCIERTO ET AL: "Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types", CLINICAL CANCER RESEARCH, vol. 19, no. 5, 1 March 2013 (2013-03-01), pages 1009 - 1020, XP055124339, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-2982
- [T] G V LONG ET AL: "Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer", ANNALS OF ONCOLOGY, 12 September 2018 (2018-09-12), NL, XP055651364, ISSN: 0923-7534, DOI: 10.1093/annonc/mdy408
- [T] M H POLLACK ET AL: "Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma", ANNALS OF ONCOLOGY, vol. 29, no. 1, 11 October 2017 (2017-10-11), NL, pages 250 - 255, XP055651368, ISSN: 0923-7534, DOI: 10.1093/annonc/mdx642
- [T] ZHAO X ET AL: "Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors", ANNALS OF ONCOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 28, no. 8, 1 August 2017 (2017-08-01), pages 2002 - 2008, XP002789767, ISSN: 1569-8041, DOI: 10.1093/ANNONC/MDX235

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

**WO 2016176503 A1 20161103**; EP 3288982 A1 20180307; EP 3988571 A1 20220427; JP 2018514550 A 20180607;  
JP 2021105000 A 20210726; JP 2024063023 A 20240510; KR 20170138555 A 20171215; US 10174113 B2 20190108;  
US 2016340428 A1 20161124; US 2019194328 A1 20190627; US 2022135685 A1 20220505

DOCDB simple family (application)

**US 2016029877 W 20160428**; EP 16725959 A 20160428; EP 21198377 A 20160428; JP 2017556651 A 20160428; JP 2021037367 A 20210309;  
JP 2024018579 A 20240209; KR 20177033882 A 20160428; US 201615141769 A 20160428; US 201916240316 A 20190104;  
US 202117523702 A 20211110